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Rheumatoid arthritis (RA) is the most
common chronic, progressive inﬂamma-
tory systemic autoimmune disease. Syn-
ovial inﬂammation and eﬀusion lead to
destructionofarticularcartilageand joint
erosion. Patients’ ability to perform daily
activities canbe seriouslyaﬀectedby joint
destruction.
The overall prevalence of inﬂamma-
tory arthritis is estimated at 3.4 % for the
German population. The lifetime preva-
lence of RA is 2.5 % in Germany. RA is
more common in women (3.2 %) than in
men (1.9 %) [1]. RA is associated with
high societal costs due to work disability.
Societal cost is highest for early onset of
RA in a patient‘s lifetime [2]. Each year,
17% of RA patients undergo hospital-
ization [3]. RA is a painful disease with
a high prevalence and a high economic
burden for patients, their families and
society.
The therapy of RA aims at early dis-
ease control and induction of sustained
remission. Successful treatment is re-
ﬂected by sustained quality of life and
ability to work. Quality-adjusted life
years (QALYs) are an important instru-
ment to reﬂect the success of therapies
in chronic diseases like RA. Further,
inclusion of indirect costs, which are
caused by early retirement and absence
from work, is important to include in
cost-eﬀectiveness analyses.
Germany is the most important mar-
ket for biological agents in the European
Union. While only 2% of RA patients
were treated with TNF-α inhibitors in
2000, the popularity of TNF-α inhibitors
rose to 20% in 2008 [4]. Adalimumab
(ADA) was the bestselling drug in the
Germanstatutoryhealth insurance (SHI)
systemwith € 581 mn net expenditure in
2012 [5]. Despite its economic relevance,
cost-eﬀectiveness of ADA treatment for
RAhasnot beenanalyzed for theGerman
SHI system.
For international comparability, we
deviate from German Institute for Qual-
ity and Eﬃciency in Health Care’s
(IQWIG) eﬃciency frontier method [6].
We aim to analyze the cost-eﬀectiveness
of ADA treatment for RA in terms of
cost per additional QALY gained. As
results of cost-utility analyses from other
countries vary widely, we aim to identify
the main determinants of cost-eﬀective-
ness of ADA for the German context
using a modeling approach.
Model andmethods
Our cost-eﬀectiveness analysis is based
on a probabilistic lifetime model, which
incorporates direct and indirect costs of
RA and its treatment. We set up an in-
dividual patient sampling model to sim-
ulate 10,000 hypothetical patients in the
German SHI system with a cycle length
of 6 months.
Baseline patient characteristics in-
clude a mean age of 54 years (σ = 12)
and an average health assessment ques-
tionnaire (HAQ) score of 1.6 (σ = 0.6).
Of the total, 78% of the hypothetical
patients are female. Initial age, gender
and functional status correspond to pa-
tient characteristics as enrolled in the
biological arm of the German biologics
register RABBIT [7].
When patients start a treatment, they
can achieve one of three responses ac-
cording toAmericanCollege ofRheuma-
tology (ACR) criteria or fail the therapy.
Eﬀectiveness data for each possible ther-
apy is extracted from IQWIG‘s extensive
literature review, which reﬂects IQWIG’s
requirements for eﬀectiveness analysis in
Germany [8]. All reported trials were
screened for ACR response rates. For
consistency, only response rates reported
after 6 months of therapy were included.
All treatments and their characteristics
are summarized in . Table 1.
Weassumeeachtreatment inthe treat-
ment algorithm is tested for at least one
period of six months, which is common
inGermanclinicalpractice. IfnoACRre-
sponse is achieved, thepatient is switched
to the next treatment in the following cy-
cle, as shown in. Fig. 1. If ACR response
can be achieved, we assume that each re-
sponse (ACR20, ACR50 or ACR70) is
associated with an initial improvement
inHAQstatus. Weassumepatientsmain-
tain their improved status throughout the
course of a speciﬁc therapy.
In each cycle, treatment might be dis-
continued due to loss of eﬃcacy or ad-
verse events. We model treatment dis-
continuationwith aWeibull distribution.
Data found in the German biologicals
register was not suﬃcient to model be-
yond a 6-month horizon [9]. Previously
published data forGreat Britainwas used
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Table 1 Summary of treatments





ACR20 response (%) 31 28 58 –0.44266 0.01831
ACR50 response (%) 11 15 36 –0.66795 0.02610
ACR70 response (%) 4 7 19 –0.92257 0.03201
Duration shape parameter 0.51 0.49 0.73
Duration scale parameter 15.73 7.31 5.96
Direct treatment costs (Q1) 74.82  220.34  5,943.26 
Direct treatment costs (Qn) 77.99  223.51  5,757.71 
Assess ACR responseNew Treatment














Fig. 19 Individual patient
sampling simulation ap-
proachtoclinicalpathways.
Each patient’s response to
a new treatment ismea-
sured in terms of ACR re-
sponse. The patient is cy-
cled to the next available
treatment option after loss
of eﬃcacy or an adverse
event
Table 2 Direct costs ()
First quarter (Q1) Following quarters (Qn)
Methotrexatemonotherapy
Methotrexate 24.28 27.45
Folic acid 5.98 5.98
Administration and screening 44.56 44.56
Total direct costs 74.82 77.99
O’Dell Triple Therapy
Methotrexate 24.28 27.45
Folic acid 5.98 5.98
Sulfasalazine 93.67 93.67
Hydroxychloroquine 51.85 51.85
Administration and screening 44.56 44.56




Administration and screening 252.20 63.49
Total direct costs 5,943.26 5,757.71
instead [10]. As previously suggested,
functional status rebounds and patients
go back to their initial functional status
after failure of the therapy [11]. After
failure of the last therapy in the treat-
ment algorithm, patients are moved to
amaintenance dose ofMTXuntil the end
of the overall simulation time or death.
In each cycle, quality of life is com-
pared tohypotheticalnaturalprogression
and incremental QALYs are recorded.
The patient’s HAQ score is converted to
quality of life using the EQ5D question-
naire. The EQ5D’s validity and reliability
for RA has been described in [12]. HAQ
scores are converted to EQ5D according
to [13]:
EQD = .–.×HAQ–.×HAQ
Themortality risk is calculated foreach
patient in each 6-month period based on
German life tables. The life tables used
in our model are both age and gender
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Cost-eﬀectiveness of adalimumab for rheumatoid arthritis in Germany
Abstract
Background. In Germany, the clinical use of
TNF-α inhibitors in the therapy of rheumatoid
arthritis (RA) grew from 2%of treated patients
in 2000 to 20% in 2008. In 2012, adalimumab
was the bestselling drug in the statutory
health insurance systemwith net expenditure
of  581 mio.
Objectives. We aim to analyze the cost-
eﬀectiveness of adalimumab for the treatment
of RA in Germany.
Methods.We set up an individual patient
sampling lifetime model to simulate 10,000
hypothetical patients. The patients’ functional
status improves according to American
College of Rheumatology response criteria.
In each 6-month cycle, treatment might be
discontinued due to loss of eﬃcacy or adverse
events.
Results. In the base case, patients gain
7.07 quality-adjusted life years (QALYs) with
conventional synthetic therapy and 9.92
QALYs if adalimumab combination therapy
is added to the treatment algorithm. The
incremental cost-utility ratio (ICUR) is  24,492
based on German list prices. After deducting
mandatory rebates and taxes, the ICUR is
 17,277, comparing favorably to analyses in
other countries. Adalimumab combination
therapy lowers indirect costs from  162,698
to  134,363. The ICUR based on total costs
is  14,550 ( 7,335 after deducting taxes
and rebates). Sensitivity analysis shows that
adalimumab combination therapy becomes
a dominant treatment option for younger
baseline populations, i. e. adalimumab is both
more eﬀective and less expensive for baseline
age 30 due to savings in indirect costs.
Conclusions.Our complex probabilisticmodel
shows that estimationof cost-eﬀectiveness for
RA relies on the incorporation of indirect costs
and a suﬃciently long simulation horizon
to capture the complete range of possible
outcomes and the associated long-term
beneﬁts of biological treatment.
Keywords
Adalimumab · Rheumatoid arthritis · Cost
eﬀectiveness · Quality-adjusted life years ·
Germany
Kosten-Nutzen-Bewertung von Adalimumab bei Rheumatoider Arthritis in Deutschland
Zusammenfassung
Hintergrund. Der klinische Einsatz von TNF-
α-Blockern in der Therapie der Rheumatoiden
Arthritis (RA) ist in Deutschland von 2%
der behandelten Patienten im Jahr 2000
auf 20% im Jahr 2008 gestiegen. 2012
lagen die Nettokosten der Gesetzlichen
Krankenversicherung für Adalimumab (ADA)
bei  581 Mio.
Ziel der Arbeit. Wir wollen das Kosten-
Nutzen-Verhältnis von ADA in der RA-Therapie
in Deutschland analysieren.
Methoden. Ein Lebenszeitmodell simuliert die
individuellen Krankheitsverläufe von 10.000
virtuellen Patienten mit RA anhand ihres
Funktionsstatus auf Basis der Ansprechkriteri-
en des American College of Rheumatology in
sechsmonatigen Zyklen.
Ergebnisse. Im Basisfall gewinnen die Pati-
enten 7,07 qualitätskorrigierte Lebensjahre
(QALYs) mit konventioneller Arzneitherapie
und 9,92 QALYs mit ADA-Kombinationsthe-
rapie. Das inkrementelle Kosten-Nutzen-
Verhältnis (ICUR) beträgt  24.492 auf Basis
der deutschen Listenpreise. Nach Abzug
von Zwangsrabatten und Steuern liegt das
ICUR bei  17.277, was im internationalen
Vergleich günstig erscheint. Durch die ADA-
Kombinationstherapie sinken die indirekten
Kosten von  162.698 auf  134.363. Das ICUR
auf Basis der Gesamtkosten beträgt  14.550
( 7335 nach Abzug von Zwangsrabatten und
Steuern). Die Sensitivitätsanalyse zeigt, dass
die ADA-Kombinationstherapie bei jungen
Patientenmit einem Durchschnittsalter von
30 Jahren bei Behandlungsbeginn sowohl
eﬀektiver als auch insgesamt günstiger ist.
Diskussion. Unser komplexesWahrscheinlich-
keitsmodell zeigt, dass die Berücksichtigung
indirekter Kosten und ein hinreichend
langer Simulationszeitraum für die Analyse
des Kosten-Nutzen-Verhältnisses der RA-
Arzneitherapie besonders wichtig sind,
um die komplette Bandbreite möglicher
Verläufe und positive Langzeiteﬀekte des
Biologikaeinsatzes erfassen zu können.
Schlüsselwörter
Adalimumab · Rheumatoide Arthritis · Kosten-
Nutzen-Bewertung · Qualitätskorrigiertes
Lebensjahr · Deutschland
speciﬁc. If the simulation results in a pa-
tient’s death during a speciﬁc modeling
period, both costs and QALYs gained are
logged and the next of the 10,000 patients
is sampled. No inﬂuence of HAQ score
is assumed on the mortality risk [14].
As suggested by German guidelines,
all patients receive MTX monotherapy
as ﬁrst-line therapy [15]. As required
for reimbursement of biological agents,
patients are ﬁrst switched to another
conventional synthetic disease-modi-
fying antirheumatic drug (csDMARD)
therapy if MTX monotherapy fails. All
patients are switched to O’Dell’s con-
ventional synthetic triple therapy (MTX,
sulfasalazine, hydroxychloroquine) after
failure of ﬁrst-line MTX monotherapy
[16]. If triple therapy fails, patients are
switched to ADA andMTX combination
therapy in the biological armor to aMTX
maintenance dose in the conventional
arm. No comparison to other biological
agents is conducted. The model setup
makes sure that all changes in eﬀective-
ness and costs can be attributed to the
addition of ADA combination therapy
to the treatment algorithm.
Direct cost calculations include drug
costs according to the Red List 2012
and out-patient treatment costs (admin-
istration costs and screening costs before
initiation of the therapy) according to
German SHI out-patient payment condi-
tions (Einheitlicher Bewertungsmassstab,
EBM), as shown in . Table 2 and 3.
Weextendcostcomputations toreﬂect
a societal perspective. Indirect cost data
according to the human capital approach
is based on previously published data by
the German Rheumatism Research Cen-
tre Berlin reﬂecting productivity losses
1008 Zeitschrift für Rheumatologie 10 · 2016







ADA Q1 ADA Qn
01321 Quarterly base rate for autho-
rized clinics, requiring face-to-
face physician-patient contact
15.77 15.77 15.77 15.77
13700 Treatment of patientwith at
least one additional condition:
poly-oligoarthritis; seronegative
ankylosing spondylitis; connec-




diagnosis including HAQ/FFbH or
DAS scores
15.95 15.95 15.95 15.95
32045 Blood sedimentation rate 0.25 0.25 0.25 0.25
32060 Blood cholesterol level 0.25
32064 Uric acid 0.25 0.25 0.25 0.25
32065 Urea 0.25 0.25 0.25 0.25
32067 Creatinine, enzymatic 0.40 0.40 0.40 0.40
32068 Alkaline Phosphatase 0.25 0.25 0.25 0.25
32069 GOT 0.25 0.25 0.25 0.25
32070 GPT 0.25 0.25 0.25 0.25
32071 GGT 0.25 0.25 0.25 0.25
32122 Complete hemogram 1.10 1.10 1.10 1.10
32128 CRP 1.15 1.15 1.15 1.15
32823 Hepatitis B virus diagnostics 89.50
32824 Hepatitis C virus diagnostics 89.50
33050 Joint sonography 7.89 7.89 7.89 7.89
34220 Chest x-ray 9.46
40120 Mail 0.55 0.55 0.55 0.55
Sum 44.56 44.56 252.20 63.49














Patient age < 45 766.40 4,765.59 14,775.61 21,788.45 31,119.47
Patient age 45–54 2,080.04 6,212.24 16,898.71 25,203.66 33,242.58
Patient age 55–64 5,135.49 9,944.15 18,255.42 23,314.90 28,198.30
Patient age ≥ 65 – – – – –
Table 5 Base case results
ADA arm csDMARD arm Incremental
Direct costs (in ) 76,118 6,318 69,800
Indirect costs (in ) 134,363 162,698 –28,334
Mean total costs (in ) 210,481 169,016 41,465
Mean QALYs 9.92 7.07 2.85
Cost-utility (incremental
cost per QALY gained)
14,550
basedonitsNationalDatabaseof theGer-
man Collaborative Arthritis Centres, as
shown in. Table 4 [17, 18]. As described
indetail in [17], indirect costs reﬂect pro-
ductivity losses due to patients’ sick-leave
days and permanent work disability, i. e.
early retirements. Costs for sick leaves
comprise the number of days of absence,
which could be attributed to patients’
RA. Costs for a sick day are assumed to
be equivalent to an average daily wage
in Germany. Indirect costs are applied
according to functional status and age,
as described in [18]. All costs are dis-
counted or inﬂated at an annual rate of
3% to 2012 level, as required by IQWIG
[19]. As the available published data uses
theGermanHannoverFunctionalAbility
Questionnaire (FFbH) rather than HAQ,
the cutoﬀ values for the functional status
classes were converted to HAQ by linear




ventional synthetic therapy, on average,
gain 7.07 QALYs over their lifetime. The
average expected direct costs would be
€ 6,318, while expected total costs would
be € 169,016 over a patient’s lifetime.
Addition of ADA combination therapy
to the treatment algorithm results in an
expected lifetimegainof 9.92QALYs. Di-
rect costs rise to € 76,118 while overall
expected costs rise to € 210,481. In the
base case, the incremental cost-utility ra-
tio (ICUR) per additional QALY gained
by ADA combination therapy is € 24,492
if only direct costs are considered. The
ICUR is € 14,550 if indirect costs are
included, too. The base case results are
summarized in . Table 5. . Table 6 pro-
vides a summary of the clinical pathways.
WhilenoICURthresholdhasbeende-
ﬁned for Germany, € 60,000 per QALY
gained is a value that is known to be ac-
cepted for treatments by the SHI funds
in Germany. This value has been sug-
gested for cost-utility analysis of biologi-
cal agents inGermany[21]. TheICURfor
the base-case is well below this threshold




















































































































































































































































































































































































































































































































































































































































































































































































































for both direct and total costs per QALY
gained.
The results reported for the base case
potentially overestimate German ICURs
for international comparison. In con-
trast to other countries like Sweden or
the United Kingdom, German pharma-
ceutical list prices are distorted by inclu-
sion of the full value-added tax (VAT) of
19% and a mandatory rebate, which is
reimbursed by the manufacturer to the
SHI funds. Taxes are used to subsidize
theGerman SHI funds on a regular basis.
The mandatory rebate is subject to the
political decision making process. It fre-
quently changes with new government
coalitions. For the purpose of our analy-
sis, we assume a 16% mandatory rebate,
whichhasbeenapplied fromAugust2010
to December 2013.
For the base case, direct costs are only
€ 54,507 for ADA combination therapy
and € 5,269 for conventional monother-
apy if VAT andmandatory rebates are ex-
cluded from cost calculations. Adjusted
ICURs are € 17,277 for direct costs and
€ 7,335 for total costs.
Sensitivity analysis
Results of cost-eﬀectiveness analyses for
biological agents vary greatly, to some
extent due to diﬀerent assumptions in
the underlying models. We analyze the
impact of various changes in our model
parameters. For international compari-
son, all results of the sensitivity analysis
are reported with VAT/rebate-adjusted
results in brackets.
We test the impact of changes in pa-
tient characteristics. We alter baseline
age to 30 years, 40 years and 60 years.
We alter initial HAQ score to 1.0, 2.0
and 2.5. We further change the discount
rate of all costs to 0% and to 6%. Ad-
ditionally, we introduce a 3% discount
rate for QALYs gained as suggested in
[22]. We limit the modeling period to
5 years and to 10 years instead of the base
case’s lifetime perspective. All results are
summarized in . Table 7.
The biggest increase in ICURs can be
seen by limiting the simulation period. If
the maximum simulation period is lim-
ited to 10 years, ICURs double. The ef-
fect is even bigger for a limit of 5 years.




























































































































































































































































































































































































































































































































































































































































































































































































































(€ 61,185). ICURs for total costs rise to
€ 58,503 (€ 33,250). This ﬁnding em-
phasizes that a longer time horizon is
necessary to capture the long-term ben-
eﬁts of biological therapy as a treatment
option after the failure of csDMARDs.
The magnitude of ICUR changes
caused by discounting changes implies
that careful attention needs to be paid
to discounting assumptions, when com-
paring results among diﬀerent models.
Diﬀerent scenarios for the average
age of the hypothetical population have
a small eﬀect on ICURs if only direct
costs are considered. Baseline age eﬀect
increases if indirect costs are included
in the cost-utility analysis. For baseline
age 30, ICURs based on gross costs
decrease by 76% to € 3,493. If rebates
and VAT are deducted, ADA is a domi-
nant treatment, i. e. patients gain more
QALYs (14.90 vs. 10.55) at lower total
costs (€ 418,105 vs. € 428,317).
Total costs rise with baseline HAQ.
Fewer QALYs are gained and patients re-
main in a bad functional state, whichpre-
vents them from working. ICURs were
slightly worse for a baseline HAQ of 1.0
instead of the base case’s 1.6, perhaps in-
dicating that patients with a HAQ score
of 1.0 cannot beneﬁt as much from bi-
ological therapy as patients with a HAQ
score between 1.0 and 2.0.
If quality of life is not calculated by
conversion of HAQ scores to EQ5D but
by a diﬀerent questionnaire, the HUI-3
as proposed in [23], ICURs rise.
ICURs rise and fall with direct costs
and even more so if ICURs are based on
total costs. If indirect costs rise, the ICUR
for ADA combination therapy falls and
vice versa. This explains why ICURs in
Germany are fairly low despite high list
prices for ADA. In lower-income coun-
tries like Colombia, the ICUR for bio-
logical therapy has been reported to be
€ 137,723 due to much lower indirect
costs [24].
. Fig. 2 shows the cost-eﬀectiveness
acceptability curve (CEAC) for the base
case. TheCEAC is an important decision
tool for the regulator to measure the un-
certainty associated with accepting ADA
therapy at a speciﬁc ICUR threshold [25].
Even for the most restrictive threshold,
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Fig. 29 Cost-eﬀective-
ness acceptability curve for
the base case scenario.The
curve shows the percent-
age of simulated patients,
whose treatmentwithadal-
imumab combination ther-
apywould fulﬁll a speciﬁc
incremental cost-utility ra-
tio (ICUR), which the regu-
lator can deﬁne
i. e. € 0.00 per additional QALY gained,
the treatment of more than 30% of the
simulated population would be cost-ef-
fective.
Our sensitivity analysis helps to iden-
tify patient subgroups that belong to the
30% of cost-eﬀectively treated patients.
The sensitivity analysis suggests young
patients can be treated most cost-eﬀec-
tively, because their direct cost increases
areovercompensatedbyindirectcost sav-
ings.
The individual sampling approach
shows that ADA therapy will not meet
the threshold for 35% of patients even if
the threshold is set is as high as € 100,000,
i. e. some patients might incur high costs
under ADA therapy without beneﬁting
from the therapy in a way that would be
considered cost-eﬀective.
Discussion and conclusions
Despite ADA’s clinical and economic
relevance over the last years, our study
is the ﬁrst one to assess its cost-eﬀec-
tiveness for the German SHI system.
We could only identify one previously
published cost-eﬀectiveness analysis for
a TNF-α inhibitor for RA in Germany
[18]. Cost per QALY gained is estimated
at € 38,700 Euro for etanercept combina-
tion therapy. The study was conducted
on a 10-year time horizon, including
indirect costs. Other studies analyzed
second-line biologic agents after the
failure of a TNF-α inhibitor [26, 27].
Only one reported incremental cost-per-
QALY ratios. Adding rituximab to the
treatment algorithm after failure of etan-
ercept resulted in an ICUR of € 24,517
for direct costs only. The ICUR was only
€ 15,565 if indirect costs were included
[27].
The results of our analysis suggest that
ADA is a cost-eﬀective biological agent,
which is beneﬁcial to the patient and so-
ciety as a whole, when used after the
failure of conventional therapy. Multiple
factors contribute to ADA’s cost-eﬀec-
tiveness in Germany. Clinical evidence
shows ADA’s superior eﬀectiveness after
failure of MTX when used as a combina-
tion therapy [28]. Ourmodel reﬂects this
ﬁnding with higher QALY gains in the
biological arm. ADA’s eﬀectiveness often
prevents long-term loss of work capacity,
when the patient is at high risk after the
failure of csDMARDs.
This is further emphasizedby theﬁnd-
ing that ADA becomes more cost-eﬀec-
tive for younger populations, i. e. pop-
ulations who have more time left until
retirement. In addition to population
age, derivation of quality of life from
functional status and discounting of fu-
ture QALYs gained are decisive factors
for the cost-eﬀectiveness of ADA com-
bination therapy. This should be kept in
mind when designing cost-eﬀectiveness
models for biological treatments for RA.
Even if only direct costs are consid-
ered, the ICUR found in our analysis for
ADA combination therapy (€ 24,492)
compares favorably to results found
for Sweden (€ 34,922), Great Britain
(£ 34,300) and China ($ 57,926) [23, 29,
30]. However, international comparison
of results remains diﬃcult due to dif-
ferences in methodology, even though
the same measure of cost-eﬀectiveness
is used, i. e. cost per additional QALY
gained.
Our analysis has shown that ADA
combination therapy is cost-eﬀective by
all known standards for the German SHI
system. Cost-eﬀectiveness is heavily in-
ﬂuenced by indirect costs because of RA’s
inﬂuence on the patients’ ability to work.
For a very young population (baseline
age 30), direct costs incurred by biolog-
ical treatment are overcompensated by
indirect cost savings at a higher quality
of life for the patient.
Due to the lack of head-to-head com-
parisons of biological agents, further
modeling approaches are needed to com-
pare the cost-eﬀectiveness of diﬀerent
biological agents for the German mar-
ket. Further opportunities might arise
by earlier use of biological agents before
the failure of multiple conventional ther-
1014 Zeitschrift für Rheumatologie 10 · 2016
apies. If a window of opportunity exists
in early RA, use of biological agents as
ﬁrst-line therapy could be cost-eﬀective
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